{
    "id": 6571,
    "name": "non-invasive bladder urothelial carcinoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:6571",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00794950",
            "title": "Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03317158",
            "title": "ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 6536,
                    "therapyName": "BCG solution + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03672240",
            "title": "Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8517,
                    "therapyName": "APL-1202",
                    "synonyms": null
                },
                {
                    "id": 8518,
                    "therapyName": "APL-1202 + BCG solution",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04149574",
            "title": "A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6921,
                    "therapyName": "BCG solution + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4455,
                    "therapyName": "BCG solution",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04172675",
            "title": "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu\u00e9rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1133,
                    "therapyName": "Mitomycin C",
                    "synonyms": null
                }
            ]
        }
    ]
}